The Challenge of Pharma Effluent

Pharmaceutical manufacturing generates effluent with high COD, active pharmaceutical ingredients (APIs), antibiotics, solvents and variable pH. Conventional biological treatment alone often fails to meet the strict discharge limits set by regulators and the Good Manufacturing Practice (GMP) expectations of multinational buyers. EPC contractors in Saudi Arabia, Indonesia and Vietnam increasingly specify advanced oxidation followed by membrane bioreactor (MBR) polishing.

Why Ozone Catalyst + MBR Is the Preferred Route

Ozone catalytic oxidation breaks recalcitrant organics into biodegradable fragments and reduces color, odor and toxicity. When followed by an MBR with ultrafiltration membranes, the system delivers a compact footprint, high-quality effluent and reliable pathogen removal. The combination is especially attractive for pharmaceutical plants where land is limited and discharge standards are tightening.

Process Comparison: Biological Only vs. Ozone Catalyst + MBR

Parameter	Conventional Biological	Ozone Catalyst + MBR
COD removal	60–80%	90–98%
API/degradation	Limited	High via ·OH radicals
Effluent turbidity	10–30 NTU	<1 NTU
Footprint	Large clarifier area	40–60% smaller
Sludge volume	Higher	Lower, dewatered by screw press
Reuse potential	Limited	Suitable for RO pre-treatment

Regional Compliance and Procurement Landscape

Saudi Arabia

Saudi Food and Drug Authority (SFDA) and Ministry of Environment, Water and Agriculture (MEWA) enforce strict limits on pharmaceutical discharge. Projects in King Abdullah Economic City and Jeddah industrial zones require validated treatment trains, often with online COD and TOC analyzers.

Indonesia

Indonesia’s Ministry of Health and KLHK monitor pharmaceutical effluent under industrial wastewater regulations. Foreign investors building active-ingredient plants in Java and Sumatra prefer packaged ozone+MBR systems that can be pre-commissioned and shipped as containerized units.

Vietnam

Vietnam’s pharmaceutical sector is growing rapidly in Hanoi, Ho Chi Minh City and Binh Duong. Provincial Departments of Natural Resources and Environment (DONRE) are stepping up inspections. A containerized ozone catalyst + MBR plant provides fast deployment and documented performance guarantees.

Design Checklist for EPC Teams

• Conduct wastewater characterization: COD, BOD, TSS, pH, antibiotics, solvents, heavy metals.
• Size ozone catalyst reactor based on COD target and contact time (typically 15–45 minutes).
• Select MBR membrane flux to match peak flow and peak organic load.
• Include equalization tank to dampen batch discharge variability.
• Specify sludge dewatering—commonly a screw press or centrifuge—for reduced disposal cost.
• Integrate online COD, pH and flow meters for compliance reporting.

Conclusion

For pharmaceutical EPC projects, the ozone catalyst + MBR route offers a robust, compact and compliance-ready solution. It addresses the dual pressure of strict effluent limits and limited plant footprint, making it suitable for both greenfield facilities and facility upgrades.

Planning a pharmaceutical wastewater treatment project? Request a process design and budget estimate from our application engineers.